Alnylam Pharma (ALNY) Tops Q4 EPS by 19c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alnylam Pharmaceuticals (ALNY) PT Lowered to $160 at BMO Capital
February 8, 2018 12:41 PM ESTBMO Capital lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $160.00 (from $165.00) while maintaining an Outperform rating.
Analyst Do Kim commented, "Alnylam reported 4Q17 GAAP EPS of ($1.48), below our ($1.28) estimate and Street's ($1.38). The wider loss was driven by higher expenses due to... More
